Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2011-005991-40
    Sponsor's Protocol Code Number:CVAL489K2306
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2015-06-15
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2011-005991-40
    A.3Full title of the trial
    A 6 Week, Randomized, Multicenter, Double-blind, Double-dummy Study to Evaluate the Dose Response of Valsartan on Blood Pressure Reduction in Children 1-5 Years Old With Hypertension, With or Without Chronic Kidney Disease, Followed by a 20 Week Openlabel
    Titration Phase
    Estudio de 6 semanas aleatorizado, multicéntrico, doble ciego y con doble simulación para evaluar la respuesta a la dosis de valsartán en términos de reducción de la presión arterial en niños de 1 a 5 años con hipertensión, con o sin enfermedad renal crónica, seguido de una fase abierta de ajuste de la dosis de 20 semanas.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Efficacy, safety and tolerability of multiple doses of valsartan in
    children with hypertension with or without chronic kidney disease
    Eficacia, seguridad y tolerabilidad de múltiples dosis de valsartán en niños con hipertensión con o sin enfermedad renal crónica.
    A.4.1Sponsor's protocol code numberCVAL489K2306
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorNovartis Pharma Services AG
    B.1.3.4CountrySwitzerland
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportNovartis Pharma Services AG
    B.4.2CountrySwitzerland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationNovartis Farmacéutica, S.A.
    B.5.2Functional name of contact pointDepartamento Médico
    B.5.3 Address:
    B.5.3.1Street AddressGran Via de les Corts Catalanes, 764
    B.5.3.2Town/ cityBarcelona
    B.5.3.3Post code08013
    B.5.3.4CountrySpain
    B.5.4Telephone number+34900353036
    B.5.5Fax number+34932479903
    B.5.6E-maileecc.novartis@novartis.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Diovan
    D.2.1.1.2Name of the Marketing Authorisation holderNovartis Sverige AB
    D.2.1.2Country which granted the Marketing AuthorisationSweden
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Oral solution
    D.3.4.1Specific paediatric formulation Yes
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNvalsartan
    D.3.9.2Current sponsor codeVAL489
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number3
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboOral solution
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Pediatric Hypertension With or Without CKD
    Hipertensión pediátrica con o sin enfermedad renal crónica (ERC)
    E.1.1.1Medical condition in easily understood language
    High blood pressure in paediatrics with or without chronic kidney disease
    Presión arterial alta en pacientes pediátricos, con o sin enfermedad renal crónica
    E.1.1.2Therapeutic area Diseases [C] - Cardiovascular Diseases [C14]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate if a dose dependent reduction in MSBP exists when comparing two doses of valsartan solution over a 6wk period in children 1-5 years old with hypertension with or without CKD.
    Evaluar si existe una reducción proporcional a la dosis de la PASM al comparar dos dosis de valsartán en solución durante un periodo de 6 semanas en niños de 1-5 años con hipertensión, con o sin ERC.
    E.2.2Secondary objectives of the trial
    Assess efficacy of valsartan in reducing MDBP; assess efficacy of valsartan in controlling MSBP and MDBP; to assess safety and toleribilty profile; assess proteinuria and eGFR
    Evaluar la eficacia del valsartán para reducir la PADM; evaluar la eficacia del valsartán para controlar la PASM y la PADM; evaluar el perfil de seguridad y tolerabilidad; evaluar la proteinuria y la FGe.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Patients eligible for inclusion in this study have to fulfill all of the following criteria:
    - Have the ability to provide written informed consent;
    - Have at baseline , a documented diagnosis of hypertension (as defined in the National High Blood Pressure Education Program 2004);
    - MSBP (mean of 3 measurements) must be >= 95th percentile, and <=25% above the 95th percentile, for age, gender and height, at baseline;
    - CKD patients must be defined as any of the following criteria:
    1. Kidney damage for >= 3 months, as defined by structural or functional abnormalities of the kidney, with or without decreased GFR, manifested by one or more of the following features:
    - Abnormalities in the composition of urine
    - Abnormalities in imaging tests
    - Abnormalities on kidney biopsy
    2. Estimated eGFR <60 mL/min/1.73m2 (calculated by Modified Schwartz Formula) for >= 3 months, with or without the other signs of kidney damage described above.
    - Able to swallow the valsartan solution; Body weight must be >=8 kg and <=40 kg at baseline;
    - Must be able to safely washout from other antihypertensive therapy (if applicable)
    Podrán participar en el estudio los pacientes que cumplan todos los criterios siguientes:
    - Capacidad de proporcionar consentimiento informado por escrito;
    - Tener un diagnóstico documentado de hipertensión en el momento basal (según el National High Blood Pressure Education Program 2004);
    - PASM (media de tres determinaciones) >= percentil 95 y <=25% por encima del percentil 95 para la edad, el sexo y la talla en el momento basal;
    - Los pacientes con ERC deberán cumplir alguno de los siguientes criterios:
    1. Lesión renal durante >= 3 meses, definida como anomalías estructurales o funcionales del riñón, con o sin reducción de la FG, que se manifiesta por medio de una o más de las siguientes características:
    - Anomalías en la composición de la orina
    - Anomalías en las pruebas de imagen
    - Anomalías en la biopsia renal
    2. FG estimada <60ml/min/1,73 m2 (calculada mediante la Fórmula de Schwartz modificada) durante >= 3 meses, con o sin los otros signos de lesión renal descritos anteriormente.
    - Capacidad de tragar la solución de valsartán; Peso corporal >= 8 Kg y <= 40 Kg en el momento basal;
    - Capacidad de someterse con seguridad a un lavado del tratamiento con otros antihipertensivos (si procede).
    E.4Principal exclusion criteria
    - Aspartate Aminotransferase / Serum Glutamic Oxaloacetic Transaminase (AST/SGOT) or Alanine Aminotransferase/Serum Glutamic Pyruvic Transaminases (ALT/SGPT) >3 times the upper limit of the reference range;
    - Estimated Glomerular Filtration Rate [eGFR] <30 mL/min/1.73m² (calculated using Modified Schwartz Formula); Serum potassium >5.3 mmol/L;
    - Uncontrolled diabetes mellitus, as defined by the investigator;
    - Unilateral, bilateral and graft renal artery stenosis;
    - Current diagnosis of heart failure (NYHA Class II-IV);
    - Patients taking any of the following concomitant medications following screening: RAAS blockers other than study drug, Lithium, Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and other substances that may
    increase potassium levels;
    - Non-steroidal anti-inflammatory drugs (NSAIDS), including selective COX-2 inhibitors, acetylsalicylic acid >3g/day, and non-selective NSAIDs (paracetamol/acetaminophen is permitted);
    - Antidepressant drugs in the class of MAO inhibitors (e.g. phenelzine); Chronic use of stimulant therapy for ADD/ADHD;
    - patients who have coarctation of the aorta with a gradient of >=30 mmHg;
    - Previous solid organ transplantation except renal transplantation. Renal transplant must have occurred at least 1 year prior to enrollment;
    - Patient must be on stable doses of immunosuppressive therapy and deemed clinically stable by the investigator;
    - Patients known to be positive for the human immunodeficiency virus (HIV)
    Other protocol defined inclusion/exclusion criteria may apply.
    - Aspartato Aminotransferasa/Transaminasa glutámico-oxaloacética sérica (AST/SGOT) o Alanina Aminotransferasa/ Transaminasa glutámico-pirúvica sérica (ALT/SGPT) > 3 veces el límite superior del intervalo de referencia;
    - Filtración glomerular estimada (FGe) <30 ml/min/1,73 m2 (calculada mediante la fórmula de Schwartz modificada); Potasio sérico > 5,3 mmol/l;
    - Diabetes mellitus no controlada, definida por el investigador;
    - Estenosis de arteria renal unilateral, bilateral o de injerto;
    - Diagnóstico presente de insuficiencia cardíaca (clase II-IV de la NYHA);
    - Pacientes en tratamiento concomitante con cualquiera de los medicamentos siguientes después de la selección: Antagonistas del SRAA distintos del fármaco del estudio; Litio; diuréticos ahorradores de potasio, suplementos de potasio, sustitutos de la sal que contengan potasio y otras sustancias que puedan incrementar las concentraciones de potasio; Antiinflamatorios no esteroideos (AINE), incluidos inhibidores selectivos de la COX 2, ácido acetilsalicílico en una dosis > 3 g/día y AINE no selectivos (se permite el uso de paracetamol); Antidepresivos del grupo de los inhibidores de la MAO (por ejemplo, fenelzina); Uso crónico de tratamiento estimulante por TDA/TDAH.
    - Pacientes con coartación de la aorta con un gradiente >= 30 mm Hg.
    - Trasplante de órgano sólido previo, excepto trasplante renal. El trasplante renal deberá haberse practicado al menos un año antes de la inclusión. El paciente deberá estar recibiendo dosis estables de tratamiento inmunosupresor y ser considerado clínicamente estable por parte del investigador;
    - Pacientes seropositivos para el virus de la inmunodeficiencia humana (VIH)
    También aplican otros criterios de inclusión/exclusión definidos en el protocolo.
    E.5 End points
    E.5.1Primary end point(s)
    Change from baseline (Week 0) in mean systolic blood pressure (MSBP) at Week 6 endpoint [ Time Frame: Baseline, week 6 ] [ Designated as safety issue: No ]
    Patient's blood pressure will be measured in the same position at every visit. Systolic and diastolic blood pressures will be measured three times at 2-3 minute intervals. The arithmetic mean of these three blood pressure measurements will be used as the mean office blood pressure (MSBP and MDBP) for that visit.
    Variación de la presión arterial sistólica media (PASM) entre el momento basal (semana 0) y la semana 6 . La presión arterial del paciente se medirá en la misma posición en todas las visitas. Las presiones arteriales sistólica y diastólica se medirán tres veces a intervalos de 2-3 minutos. La media aritmética de estas tres determinaciones de presión arterial se utilizará como presión arterial media en el consultorio (PASM y PADM) en esa visita.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Week 6
    Semana 6
    E.5.2Secondary end point(s)
    Change from baseline in mean diastolic blood pressure (MDBP) at Week 6 and end of study (26 weeks)
    Percentage of patients achieving MSBP < 90th percentile for age, gender and height at Week 6 endpoint and end of study (26 weeks)
    Number of patients with Urine Albumin Creatinine Ratio (UACR) response at Week 6 endpoint and end of study (26 weeks)
    Number of patients with adverse events, serious adverse events and death
    Variación de la presión arterial diastólica media (PADM) entre el momento basal y la semana 6 y el final del estudio (26 semanas)
    Porcentaje de pacientes que logren una PASM < percentil 90 para la edad, el sexo y la talla en la semana 6 y al final del estudio (26 semanas)
    Número de pacientes con respuesta del cociente albúmina/creatinina en orina (CACO) en la semana 6 y al final del estudio (26 semanas)
    Número de pacientes con acontecimientos adversos, acontecimientos adversos graves y muerte.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Weeks 6 and 26
    Semanas 6 y 26
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA22
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Belgium
    Brazil
    Germany
    Guatemala
    Hungary
    Lithuania
    Poland
    Spain
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    Ultima visita del último paciente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months1
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 130
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) Yes
    F.1.1.4.1Number of subjects for this age range: 50
    F.1.1.5Children (2-11years) Yes
    F.1.1.5.1Number of subjects for this age range: 80
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) No
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state5
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 65
    F.4.2.2In the whole clinical trial 130
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Ninguno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2015-07-16
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2015-07-09
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2017-01-24
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 12:53:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA